Shares of MorphoSys AG (ETR:MOR) have been assigned an average recommendation of “Buy” from the eight research firms that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is €81.25 ($94.48).
MOR has been the subject of several research reports. Goldman Sachs Group, Inc. (The) set a €55.00 ($63.95) price objective on shares of MorphoSys AG and gave the stock a “neutral” rating in a research report on Thursday, September 7th. Commerzbank Ag set a €76.00 ($88.37) price objective on shares of MorphoSys AG and gave the stock a “buy” rating in a research report on Thursday, August 31st. Deutsche Bank AG set a €90.00 ($104.65) price objective on shares of MorphoSys AG and gave the stock a “buy” rating in a research report on Thursday, September 7th. Independent Research GmbH set a €77.00 ($89.53) price objective on shares of MorphoSys AG and gave the stock a “buy” rating in a research report on Thursday, September 7th. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of MorphoSys AG in a research report on Wednesday, September 6th.
MorphoSys AG (ETR MOR) opened at €79.25 ($92.15) on Friday. MorphoSys AG has a 1-year low of €40.10 ($46.63) and a 1-year high of €82.20 ($95.58).
TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/12/04/morphosys-ag-mor-receives-consensus-rating-of-buy-from-analysts.html.
MorphoSys AG Company Profile
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with MarketBeat.com's FREE daily email newsletter.